This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Verma, A. Articles by Mehta, K. Search for Related Content PubMed PubMed Citation Articles by Verma, A. Articles by Mehta, K.

Increased Expression of Tissue Transglutaminase in Pancreatic Ductal Adenocarcinoma and Its Implications in Drug Resistance and Metastasis

Departments of ¹ Experimental Therapeutics, ² Pathology, and ³ Molecular and Cellular Oncology, The University of Texas M.D. Anderson Cancer Center; ⁴ Cancer Biology Program, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas

Requests for reprints: Kapil Mehta, Department of Experimental Therapeutics, Unit 362, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: 713-792-8140; Fax: 713-745-4167; E-mail: kmehta{at}mdanderson.org.

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive neoplastic diseases and is virtually incurable. The molecular mechanisms that contribute to the intrinsic resistance of PDAC to various anticancer therapies are not well understood. Recently, we have observed that several drug-resistant and metastatic tumors and tumor cell lines expressed elevated levels of tissue transglutaminase (TG2). Because PDAC exhibits inherent resistance to various drugs, we determined the constitutive expression of TG2 in 75 PDAC and 12 PDAC cell lines. Our results showed that 42 of 75 (56%) PDAC tumor samples expressed higher basal levels of TG2 compared with the normal pancreatic ducts [odds ratio (OR), 2.439; P = 0.012]. The increased expression of TG2 in PDAC was strongly associated with nodal metastasis (OR, 3.400; P = 0.017) and lymphovascular invasion (OR, 3.055; P = 0.045). Increased expression of TG2 was also evident in all 12 cell lines examined. The elevated expression of TG2 in PDAC cell lines was associated with gemcitabine resistance and increased invasive potential. Overexpression of catalytically active or inactive (C₂₇₇S mutant) TG2 induced focal adhesion kinase (FAK) activation and augmented invasive functions in the BxPC-3 cell line. Conversely, down-regulation of TG2 by small interfering RNA attenuated FAK phosphorylation. Immunoprecipitation and confocal microscopy data revealed that TG2 was associated with FAK protein in PDAC cells. The activated FAK colocalized with TG2 at focal adhesion points. These results show for the first time that elevated expression of TG2 can induce constitutive activation of FAK and thus may contribute to the development of drug resistance and invasive phenotypes in PDAC. (Cancer Res 2006; 66(21): 10525-33)

This article has been cited by other articles:

				M. Ponnusamy, M. Pang, P. K. Annamaraju, Z. Zhang, R. Gong, Y. E. Chin, and S. Zhuang Transglutaminase-1 protects renal epithelial cells from hydrogen peroxide-induced apoptosis through activation of STAT3 and AKT signaling pathways Am J Physiol Renal Physiol, November 1, 2009; 297(5): F1361 - F1370. [Abstract] [Full Text] [PDF]

				A. Luciani, V. R. Villella, A. Vasaturo, I. Giardino, V. Raia, M. Pettoello-Mantovani, M. D'Apolito, S. Guido, T. Leal, S. Quaratino, et al. SUMOylation of Tissue Transglutaminase as Link between Oxidative Stress and Inflammation J. Immunol., August 15, 2009; 183(4): 2775 - 2784. [Abstract] [Full Text] [PDF]

				M. A. Antonyak, B. Li, A. D. Regan, Q. Feng, S. S. Dusaban, and R. A. Cerione Tissue Transglutaminase Is an Essential Participant in the Epidermal Growth Factor-stimulated Signaling Pathway Leading to Cancer Cell Migration and Invasion J. Biol. Chem., July 3, 2009; 284(27): 17914 - 17925. [Abstract] [Full Text] [PDF]

				A. CHHABRA, A. VERMA, and K. MEHTA Tissue Transglutaminase Promotes or Suppresses Tumors Depending on Cell Context Anticancer Res, June 1, 2009; 29(6): 1909 - 1919. [Abstract] [Full Text] [PDF]

				M Mimeault and S K Batra Recent progress on normal and malignant pancreatic stem/progenitor cell research: therapeutic implications for the treatment of type 1 or 2 diabetes mellitus and aggressive pancreatic cancer Gut, October 1, 2008; 57(10): 1456 - 1468. [Abstract] [Full Text] [PDF]

				L. Cao, D. N. Petrusca, M. Satpathy, H. Nakshatri, I. Petrache, and D. Matei Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling Carcinogenesis, October 1, 2008; 29(10): 1893 - 1900. [Abstract] [Full Text] [PDF]

				A. J. Filiano, C. D. C. Bailey, J. Tucholski, S. Gundemir, and G. V. W. Johnson Transglutaminase 2 protects against ischemic insult, interacts with HIF1{beta}, and attenuates HIF1 signaling FASEB J, August 1, 2008; 22(8): 2662 - 2675. [Abstract] [Full Text] [PDF]

				J. Y. Hwang, L. S. Mangala, J. Y. Fok, Y. G. Lin, W. M. Merritt, W. A. Spannuth, A. M. Nick, D. J. Fiterman, P. E. Vivas-Mejia, M. T. Deavers, et al. Clinical and Biological Significance of Tissue Transglutaminase in Ovarian Carcinoma Cancer Res., July 15, 2008; 68(14): 5849 - 5858. [Abstract] [Full Text] [PDF]

				A. Verma, S. Guha, P. Diagaradjane, A. B. Kunnumakkara, A. M. Sanguino, G. Lopez-Berestein, A. K. Sood, B. B. Aggarwal, S. Krishnan, J. G. Gelovani, et al. Therapeutic Significance of Elevated Tissue Transglutaminase Expression in Pancreatic Cancer Clin. Cancer Res., April 15, 2008; 14(8): 2476 - 2483. [Abstract] [Full Text] [PDF]

				A. Verma, S. Guha, H. Wang, J. Y. Fok, D. Koul, J. Abbruzzese, and K. Mehta Tissue Transglutaminase Regulates Focal Adhesion Kinase/AKT Activation by Modulating PTEN Expression in Pancreatic Cancer Cells Clin. Cancer Res., April 1, 2008; 14(7): 1997 - 2005. [Abstract] [Full Text] [PDF]

				M. Satpathy, L. Cao, R. Pincheira, R. Emerson, R. Bigsby, H. Nakshatri, and D. Matei Enhanced Peritoneal Ovarian Tumor Dissemination by Tissue Transglutaminase Cancer Res., August 1, 2007; 67(15): 7194 - 7202. [Abstract] [Full Text] [PDF]

				U. Akar, B. Ozpolat, K. Mehta, J. Fok, Y. Kondo, and G. Lopez-Berestein Tissue Transglutaminase Inhibits Autophagy in Pancreatic Cancer Cells Mol. Cancer Res., March 1, 2007; 5(3): 241 - 249. [Abstract] [Full Text] [PDF]